Bristol Myers’ lung disease drug meets main goal in late-stage trial

Oct 12 (Reuters) – Bristol Myers Squibb said on Monday its experimental drug met the main goal of a late-stage trial in patients with idiopathic pulmonary fibrosis, a serious lung-scarring disease.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed)

Brought to you by www.srnnews.com

Click here to read the full article